Rani Therapeutics Holdings, Inc.
RANIAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 24, 2024 | Stifel Nicolaus | Annabel Samimy | $10.00(+143%) | $4.11 | StreetInsider |
| Mar 27, 2024 | Canaccord Genuity | Edward Nash | $9.00(+183%) | $3.18 | StreetInsider |
| Jun 13, 2022 | Wedbush | Andreas Argyrides | $28.00(+198%) | $9.40 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Chardan Capital | maintain | Buy | Oct 22, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 21, 2026 |
| Canaccord Genuity | maintain | Buy | May 20, 2026 |
| Canaccord Genuity | maintain | Buy | Apr 1, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 27, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 9, 2026 |
| Maxim Group | maintain | Buy | Oct 20, 2025 |
| Oppenheimer | maintain | Outperform | May 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 3, 2025 |
| Canaccord Genuity | maintain | Buy | Feb 26, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 25, 2024 |
| BTIG | maintain | Buy | May 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 7, 2024 |
| Canaccord Genuity | maintain | Buy | Mar 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 25, 2024 |
| Wedbush | maintain | Outperform | Feb 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 20, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 8, 2023 |
| B of A Securities | maintain | Buy | Aug 21, 2023 |
| Wedbush | maintain | Outperform | Aug 17, 2023 |
Earnings History
Next report: Mar 31, 2027 · EPS est. $-0.05| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.04 | $-0.05 | $1.7M | $925.0K |
| May 15, 2026 | $-0.04 | $-0.06 | $1.7M | $1.1M |
| Mar 26, 2026 | $-0.07 | $-0.03 | $1.5M | $5.0M |
| Nov 6, 2025 | $-0.12 | $-0.09 | — | $5.0M |
| Aug 7, 2025 | $-0.18 | $-0.19 | — | — |
| May 13, 2025 | $-0.22 | $-0.22 | $172.0K | — |
| Mar 31, 2025 | $-0.27 | $-0.24 | $1.0M | — |
| Nov 14, 2024 | $-0.24 | $-0.22 | — | — |
News
Rani Therapeutics NASDAQ: RANI outlined progress for its oral biologics delivery platform, including plans to advance its obesity program RT-114 and expectations for additional milestones from its collaboration with Chugai.
SAN JOSE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company's management team will participate in a fireside chat at the upcoming Chardan Healthcare Conference. Details below:
~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~ ~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~
SAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company's management team will participate in the upcoming September conferences.
Rani Therapeutics NASDAQ: RANI outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity.
~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~ ~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~ ~ Completed a $20 million registered direct offering ~ ~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel o…
SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company's management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below: